Literature DB >> 18341586

The antibacterial and antifungal properties of trappin-2 (pre-elafin) do not depend on its protease inhibitory function.

Kévin Baranger1, Marie-Louise Zani, Jacques Chandenier, Sandrine Dallet-Choisy, Thierry Moreau.   

Abstract

Trappin-2 (also known as pre-elafin) is an endogenous inhibitor of neutrophil serine proteases and is involved in the control of excess proteolysis, especially in inflammatory events, along with the structurally related secretory leucocyte proteinase inhibitor. Secretory leucocyte proteinase inhibitor has been shown to have antibacterial and antifungal properties, whereas recent data indicate that trappin-2 has antimicrobial activity against Pseudomonas aeruginosa and Staphylococcus aureus. In the present study, we tested the antibacterial properties of trappin-2 towards other respiratory pathogens. We found that trappin-2, at concentrations of 5-20 microm, has significant activity against Klebsiella pneumoniae, Haemophilus influenzae, Streptococcus pneumoniae, Branhamella catarrhalis and the pathogenic fungi Aspergillus fumigatus and Candida albicans, in addition to P. aeruginosa and S. aureus. A similar antimicrobial activity was observed with trappin-2 A62D/M63L, a trappin-2 variant that has lost its antiprotease properties, indicating that trappin-2 exerts its antibacterial effects through mechanisms independent from its intrinsic antiprotease capacity. Furthermore, the antibacterial and antifungal activities of trappin-2 were sensitive to NaCl and heparin, demonstrating that its mechanism of action is most probably dependent on its cationic nature. This enables trappin-2 to interact with the membranes of target organisms and disrupt them, as shown by our scanning electron microscopy analyses. Thus, trappin-2 not only provides an antiprotease shield, but also may play an important role in the innate defense of the human lungs and mucosae against pathogenic microorganisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18341586     DOI: 10.1111/j.1742-4658.2008.06355.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  34 in total

1.  Anti-HIV-1 activity of elafin is more potent than its precursor's, trappin-2, in genital epithelial cells.

Authors:  Anna G Drannik; Kakon Nag; Xiao-Dan Yao; Bethany M Henrick; Sumiti Jain; T Blake Ball; Francis A Plummer; Charles Wachihi; Joshua Kimani; Kenneth L Rosenthal
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

2.  Functional characterization of polymorphisms in the peptidase inhibitor 3 (elafin) gene and validation of their contribution to risk of acute respiratory distress syndrome.

Authors:  Paula Tejera; D Shane O'Mahony; Caroline A Owen; Yongyue Wei; Zhaoxi Wang; Kushagra Gupta; Li Su; Jesus Villar; Mark Wurfel; David C Christiani
Journal:  Am J Respir Cell Mol Biol       Date:  2014-08       Impact factor: 6.914

3.  A functional variant of elafin with improved anti-inflammatory activity for pulmonary inflammation.

Authors:  Donna M Small; Marie-Louise Zani; Derek J Quinn; Sandrine Dallet-Choisy; Arlene M A Glasgow; Cecilia O'Kane; Danny F McAuley; Paul McNally; Sinéad Weldon; Thierry Moreau; Clifford C Taggart
Journal:  Mol Ther       Date:  2014-09-05       Impact factor: 11.454

4.  Functional study of elafin cleaved by Pseudomonas aeruginosa metalloproteinases.

Authors:  Nicolas Guyot; Gudmundur Bergsson; Marcus W Butler; Catherine M Greene; Sinéad Weldon; Efrat Kessler; Rodney L Levine; Shane J O'Neill; Clifford C Taggart; Noel G McElvaney
Journal:  Biol Chem       Date:  2010-06       Impact factor: 3.915

5.  Periodontal pathogens affect the level of protease inhibitors in gingival crevicular fluid.

Authors:  O Laugisch; M Schacht; A Guentsch; T Kantyka; A Sroka; H R Stennicke; W Pfister; A Sculean; J Potempa; S Eick
Journal:  Mol Oral Microbiol       Date:  2011-12-07       Impact factor: 3.563

6.  The adult boar testicular and epididymal transcriptomes.

Authors:  Benoît Guyonnet; Guillemette Marot; Jean-Louis Dacheux; Marie-José Mercat; Sandrine Schwob; Florence Jaffrézic; Jean-Luc Gatti
Journal:  BMC Genomics       Date:  2009-08-07       Impact factor: 3.969

7.  Evolution of trappin genes in mammals.

Authors:  Akira Kato; Alejandro P Rooney; Yutaka Furutani; Shigehisa Hirose
Journal:  BMC Evol Biol       Date:  2010-01-29       Impact factor: 3.260

8.  Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract.

Authors:  Mimi Ghosh; Zheng Shen; John V Fahey; Susan Cu-Uvin; Kenneth Mayer; Charles R Wira
Journal:  Immunology       Date:  2009-07-18       Impact factor: 7.397

Review 9.  Cytokine-mediated regulation of antimicrobial proteins.

Authors:  Jay K Kolls; Paul B McCray; Yvonne R Chan
Journal:  Nat Rev Immunol       Date:  2008-11       Impact factor: 53.106

10.  Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.

Authors:  Irina Petrache; Joud Hajjar; Michael Campos
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.